Monday June 19, 2017
PBMs and health-care groups praised the recent U.S. Supreme Court decision that is expected to accelerate patients’ access to biosimilar medications.
The ruling in the case, Sandoz Inc. v. Amgen Inc., allows biosimilar manufacturers to give marketing notice before FDA approval so that their products can get to market quicker.
“The Supreme Court’s decision today is a huge victory for American patients and consumers,” said Chip Davis, President and CEO of the Association for Accessible Medicines (AAM). “This ruling will help provide faster access to lower-cost biosimilar medicines for millions of patients facing diseases such as several forms of cancer, rheumatoid arthritis, psoriasis, multiple sclerosis, and other life-threatening conditions.”
“This ruling should help expand access and lower prescription drug costs for employers, health plans, labor unions, and Medicare,” said PBM Express Scripts in a statement provided to Drug Topics. “At a time when the cost of complex biologic specialty drugs is growing at double-digit rates, payers need every tool in their arsenal to bring cost-effective solutions to market. Express Scripts continues to champion for a clear pathway to expand the appropriate use of biosimilars.”
Read the full article on Modern Medicine Network
